Biomarker ID | 1974 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation status of FLNC |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethlated in Recurrent prostate cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Recurrent prostate cancer Vs nonrecurrent cancer |
Type of Biomarker | Prognostic |
Cohort | Recurrence (n = 123) versus nonrecurrence (n = 75) |
Senstivity | Training: 79.6 (70.3–87.1); validation:70.3 (45.7–88.1) |
Specificity | Training: 81.7 (69.6–90.5); validation:60.4 (36.0–80.8) |
AUC | Training: 0.864; Validation: validation: 0.66 |
Accuracy | NA |
Level Of Significance | <0.0001 |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | FLNC |